company background image
APS logo

Aptose Biosciences TSX:APS Stock Report

Last Price

CA$0.32

Market Cap

CA$18.7m

7D

-7.4%

1Y

-89.6%

Updated

12 Jan, 2025

Data

Company Financials

APS Stock Overview

A clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. More details

APS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Aptose Biosciences Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aptose Biosciences
Historical stock prices
Current Share PriceCA$0.32
52 Week HighCA$3.11
52 Week LowCA$0.19
Beta0.97
1 Month Change21.15%
3 Month Change-35.71%
1 Year Change-89.60%
3 Year Change-98.76%
5 Year Change-99.73%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

Mar 26
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Dec 08
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aug 05
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Apr 02
We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Sep 30
Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Feb 07
Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Jan 03
Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Nov 29
We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Shareholder Returns

APSCA BiotechsCA Market
7D-7.4%-3.7%-1.3%
1Y-89.6%10.2%15.5%

Return vs Industry: APS underperformed the Canadian Biotechs industry which returned 10.2% over the past year.

Return vs Market: APS underperformed the Canadian Market which returned 15.5% over the past year.

Price Volatility

Is APS's price volatile compared to industry and market?
APS volatility
APS Average Weekly Movement26.5%
Biotechs Industry Average Movement12.9%
Market Average Movement8.3%
10% most volatile stocks in CA Market18.2%
10% least volatile stocks in CA Market2.9%

Stable Share Price: APS's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: APS's weekly volatility has increased from 15% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198636William Ricewww.aptose.com

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.

Aptose Biosciences Inc. Fundamentals Summary

How do Aptose Biosciences's earnings and revenue compare to its market cap?
APS fundamental statistics
Market capCA$18.75m
Earnings (TTM)-CA$51.66m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$35.80m
Earnings-US$35.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.60
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-109.5%

How did APS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 02:24
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptose Biosciences Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan DupuisB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Joseph PantginisH.C. Wainwright & Co.